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Abstract: 
The secretome of human amniotic fluid stem cells (AFSC) has great 
potential as a therapeutic agent in regenerative medicine. However it must 
be produced in a clinically compliant manner before it can be used in 
humans. Here we developed a means of producing a biologically active 
secretome from AFSCs that is free of all exogenous molecules. We 
demonstrate that the full secretome is capable of promoting stem cell 
proliferation, migration and protection of cells against senescence. 
Furthermore, it has significant anti-inflammatory properties. Most 
importantly we show that it promotes tissue regeneration in a model of 
muscle damage. We then demonstrate that the secretome contains 
extracellular vesicles (EV) that harbour much but not all the biological 
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activity of the whole secretome. Proteomic characterisation of the EV and 
free secretome fraction show the presence of numerous molecules specific 
to each fraction that could be key regulators of tissue regeneration. 
Intriguingly we show that the EVs only contain miRNA and not mRNA. This 
suggests tissue regeneration in the host is mediated by the action of EVs 
modifying existing, rather than the imposition of new, signalling pathways. 
The EVs harbour significant anti-inflammatory activity as well as promoting 
angiogenesis; the latter may be the mechanistic explanation for their 
ability to promote muscle regeneration after cardiotoxin injury. 
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Abstract 
The secretome of human amniotic fluid stem cells (AFSC) has great potential as a therapeutic agent 
in regenerative medicine. However it must be produced in a clinically compliant manner before it 
can be used in humans. Here we developed a means of producing a biologically active secretome 
from AFSCs that is free of all exogenous molecules. We demonstrate that the full secretome is 
capable of promoting stem cell proliferation, migration and protection of cells against senescence. 
Furthermore, it has significant anti-inflammatory properties. Most importantly we show that it 
promotes tissue regeneration in a model of muscle damage. We then demonstrate that the 
secretome contains extracellular vesicles (EV) that harbour much but not all the biological activity of 
the whole secretome. Proteomic characterisation of the EV and free secretome fraction show the 
presence of numerous molecules specific to each fraction that could be key regulators of tissue 
regeneration. Intriguingly we show that the EVs only contain miRNA and not mRNA. This suggests 
tissue regeneration in the host is mediated by the action of EVs modifying existing, rather than the 
imposition of new, signalling pathways. The EVs harbour significant anti-inflammatory activity as well 
as promoting angiogenesis; the latter may be the mechanistic explanation for their ability to 
promote muscle regeneration after cardiotoxin injury. 
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Introduction 
 
Stem cells are able to undergo numerous asymmetric cell divisions giving rise to one daughter that 
reverts to its parental state and the other capable of differentiation [1]. In a classical scenario, the 
differentiated cell carries out repair of only the resident tissue. However an extensive body of 
research has shown that in many cases the differentiating cell is multipotent. These findings have 
been exploited to develop therapies in which one conveniently isolated stem cell population can be 
used to treat numerous damaged tissues [2,3]. As such, it is assumed that stem cells make a direct 
cellular contribution to the regenerated tissue. However in many instances following the 
introduction of stem cells, robust tissue regeneration was evident but with minimal stem cell 
engraftment [4-6]. This had led to a paradigm shift in our understanding of stem cell mediated tissue 
repair through the proposition that stem cells secrete molecules which activate host cells that are 
the cellular mediators of regeneration [7]. The notion of a paracrine effect is supported by many 
studies which show that stem cells secrete a spectrum of proteins, small RNAs and mRNAs which 
have biological activity [8-10]. In this scenario, secreted stem cell factors modulate host cellular 
signalling pathways e.g. promoting an anti-inflammatory response or by protecting against 
senescence [4,11,12]. A number of studies have shown that factors released by stem cells are 
packaged in a variety of phospholipid membrane bound extracellular vesicles (EVs), including 
microvesicles and exosomes [10,13]. Several species of EV, such as exosomes, are shed constitutively 
but more so during cellular stress [14]. Release of EVs from the cell is believed to enable effective 
long-range signal transduction by protecting the cargo against degradation. Furthermore it is 
proposed that molecules on the surface of EVs permit homing to specific tissues, thereby facilitating 
a degree of target specificity [15].  
Numerous studies have focused on identifying an optimal population for stem cell therapies by 
taking into account differentiation repertoire, ease of isolation, longevity and any associated ethical 
issues. One particularly attractive source is amniotic fluid derived stem cells (AFSCs). These cells 
support the regeneration of bone [2], lung [16], kidney [17,18], intestine [4], heart [19] and skeletal 
muscle [20,21]. They are easily isolated from human amniotic fluid which is routinely collected 
during clinical prenatal diagnostic procedures such as amniocentesis and which is not associated 
with any ethical issues. Furthermore human AFSCs have been shown capable of approximately 250 
population doublings [22]. However in many reports, regeneration takes place without significant 
AFSC engraftment again pointing to a paracrine mechanism of action [4,9].   
In this study we determined whether a human AFSC secretome collected under conditions 
concordant with clinical translation would support tissue regeneration. Specifically we wanted to 
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obviate contamination with non-human proteins/molecules including those found in foetal calf 
serum. We developed conditions which allowed the collection of a secretome which was not only 
serum free but induced cellular stress without promoting cell death. Here we report that the human 
AFSC secretome produced in nutrient free and hypoxic conditions contains a spectrum of proteins 
and miRNA. The whole secretome protected against senescence and promoted stem cell 
proliferation and migration. Using reporter cell lines we demonstrate significant anti-inflammatory 
potential of the human AFSC conditioned media (AF-CM). In vivo experiments show that the AF-CM 
promoted skeletal muscle regeneration. We then isolated and characterised the EV fraction (AF-EV) 
from AF-CM and showed that it too had anti-inflammatory properties and protects against 
senescence. We profiled the protein and miRNA cargo of both the EV and non EV fraction and found 
that each contained specific entities. Importantly we show that AF-EVs were able to promote adult 
mouse muscle regeneration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods 
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Ethical Approval Human amniotic fluid samples were collected from women having amniocentesis 
for prenatal diagnosis for therapeutic purposes in Fetal Medicine Unit of University College London 
Hospital (UCLH). All patients gave informed written consent to an approved researcher under ethical 
approval (UCL/UCLH Joint Committee for the Ethics of Human Research, REC Reference: 08/0304).  
Invasive procedures were performed under ultrasound guidance using sterile equipment.  In vivo 
animal experiments were performed under a project license from the United Kingdom (UK) Home 
Office, in agreement with the Animals (Scientific Procedures) Act 1986. 
 
Animal Maintenance Male wild-type C57BL/6 mice (2-3 month-old) were maintained in accordance 
with the Animals (Scientific Procedures) Act 1986 (UK). Mice were housed under standard 
environmental conditions (20–22 °C, 12–12 h light–dark cycle), and were provided with food and 
water ad libitum. 
 
Cell culture Human amniotic fluid stem cells were harvested from a single amniotic fluid sample 
based on C-kit expression using MACS (Miltenyi Biotec) following 1 passage. C-kit
+
 AFSCs were 
cultured on non-tissue culture treated plastic in α-MEM medium (Gibco, Invitrogen) containing 15% 
FBS, 1% glutamine and 1% penicillin/streptomycin (Gibco), supplemented with 18% Chang B and 2% 
Chang C (Irvine Scientific).  
U251 cells were cultured in antibiotics- free DMEM (Gibco), 10% FBS, 1% glutamine.  
Human foetal IMR-90 Lung Fibroblast cells (IMR-90) were a gift of Dr. Debacq-Chainiaux (University 
of Namur, Belgium). Cells were used at 27-30 population doublings. IMR-90 cells were cultured in α- 
MEM medium containing 10% FBS, 1% glutamine and 1% penicillin/streptomycin. 
StemPro® Human Adipose Derived Stem Cells (hADMSCs; Life Technologies – lot 2117), derived from 
a 49 year old female donor were from Stem Pro (lot no. 2117). hADMSCs were cultured in MesenPro 
RS
TM
 (Gibco), 1% L-glutamine, 1% penicillin/streptomycin. 
All cells were cultured at 37 °C with 5% CO2 and passaged upon reaching 70% confluency unless 
otherwise stated. 
 
Conditioned media (CM) generation and extracellular vesicle (EV) isolation At 10 passage,  AFSCs 
were pelleted at 300g in 1.5 mL microfuge tubes at a density of 1x10
6
cells/tube. Cells were 
incubated in 400μl sterile PBS for 24 hours.  Following incubation the cells were pelleted at 300 g for 
5 minutes, the supernatant was aspirated, pooled and centrifuged at 2,000 g for 20 minutes.  The 
supernatant (AF-CM) was collected and stored at -20°C. AF-EVs were isolated using sequential 
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ultracentrifugation of AF-CM at 200,000g using a 70.1Ti fixed-angle rotor (Beckman Coulter) and re-
suspending EVs in ultra-centrifuged PBS.  
 
Flow Cytometry Expression of surface markers was assessed using monoclonal antibodies against 
the cluster of differentiation (CD) antigens: anti-human CD44/Alexa Fluor® 647 (Millipore); anti-
human CD73/PE (Biolegend 1:20); anti-human CD90/PE (Millipore 1:20); anti-human CD34/FITC 
(Millipore 1:10); anti-human CD45/FITC (Biolegend 1:20).   
Post-CM generation AFSCs were fixed in 4% paraformaldehyde (Sigma Aldrich) for 20 minutes and 
non-specific binding blocked with 10% FBS (Gibco) at room temperature.  Antibodies were diluted in 
PBS and incubated with the AFSCs for 1 hour at 4°C.  10,000 events were captured and recorded 
using the BD Accuri C6 flow cytometer C-sampler. Data was analysed using the FlowJo v10 analysis 
software (FlowJo LLC). 
 
Adipogenic Differentiation AFSCs were seeded at 4000 cells per cm
2
 and grown to 95% confluency. 
Growth media was then removed, cells were washed once with PBS and cultured for 21 days with 
Stem XVivo Adipogenic Base Media (R&D Systems) supplemented with Stem XVivo Adipogenic 
Supplement (100X) according to the suppliers instructions. Cells were stained for 30 minutes with Oil 
Red O and washed with ddH2O.  
 
Osteogenic Differentiation AFSCs were seeded at 4000 cells per cm
2
 and grown to 95% confluency. 
Growth media was then removed, cells were washed once with PBS and cultured for 21 days with 
Stem XVivo Osteogenic Base Media (R&D Systems) supplemented with Stem Pro 
Osteocyte/Chondrocyte basal medium (Life Technologies) according to the supplier’s instructions. 
Calcium staining was carried out for 30 minutes using Alizarin Red S and washed with ddH2O before 
capturing images.  
 
Chondrogenic Differentiation For chondrogenic differentiation, 1x10
6
 AFSCs were pelleted at 300g. 
Cell pellets were cultured in Stem Pro Osteocyte/Chondrocyte basal medium (Life Technologies) 
supplemented with StemPro Chondrogenesis supplement (Life Technologies) according to the 
supplier’s instructions After 21 days, cells were fixed for 15 minutes in 4% PFA/PBS and washed 
twice with ddH2O. Chondrogenic cultures were stained for 1h with Alcian blue at RT. Cell pellets 
were washed twice for 1 hour in 6:4 ethanol/acetic acid de-stain solution. Pellets were washed once 
in ddH2O before freezing and blocking in OCT. 10µm cryo-sections were taken using a Bright OT5000 
cryostat. Cells and pellet sections were imaged using a bright field microscope. 
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SDS-PAGE and Silver Staining Protein concentrations in the CM were determined by using the Bio-
Rad protein assay (Bio-Rad). CM protein samples were denatured at 100ᵒC then loaded onto a pre-
cast NuPAGE®  4-12% SDS-PAGE (Novex) and run at 100V for 3 hours. Silver Staining was carried out 
using the SilverXpress® silver staining kit (Invitrogen). Protein bands were imaged using a Syngene 
G:Box and GeneSys software.  
 
Cellular Proliferation Assay hADMSCs were transferred into 96-well culture plates at a density of 
400 cells/well and allowed to adhere for 24 hours. Subsequently, media was removed before 
replacing with corresponding treatments. Cells were treated for 48 hours then washed with PBS, 
fixed with 4% PFA/PBS for 15 minutes and then washed again in PBS. Nuclei were stained with DAPI 
and nuclei counted using a fluorescent microscope (Zeiss A1). 
 
Migration Assay hADMSCs were cultured to reach 100% confluency in 24-well plates. A single 
scratch was created along the diameter of the well with a p200 tip. Media was then aspirated and 
cells washed once with PBS before treating with their corresponding media/CM treatments.  Plates 
were immediately positioned onto a time-lapse microscope and images were captured at 3 areas of 
the wound. Total wound coverage was measured using ImageJ software at T=0 hours and T=9 hours. 
 
Cellular Senescence Assay IMR-90 cells were grown in 12-well plates until 70% confluency. Media 
was removed and replaced with media containing AF-CM and left for a further 24 hours. Media was 
removed and cells were stressed for 2 hours with 100μM H2O2 in serum free media for 2 hours. 
Media was removed and cells washed twice with PBS prior to being incubated in 1ml growth media 
for 48 hours in normal culture conditions.  Cells were passaged into 3 wells of a 24-well plate at 800 
cells/well. After 24 hours, cells were fixed with 0.2% glutaraldehyde/ 2% PFA for 5 minutes. 
Subsequently, cells were then washed twice in PBS and incubated with 2.5mg/ml X-Gal solution for 
18 hours at 37ᵒC in the dark [23]. Subsequently, wells were rinsed twice with PBS and then twice 
with methanol before air drying. Cells stained blue were considered senescent and assays visualised 
using a Zeiss A1 inverted Epi-fluorescent Microscope. 
 
NF-κB p65 Nuclear Translocation Assay U251 cells were cultivated on cell-culture treated cover slips 
for 24 h. After 24 h pre-treatment with CM, cells were exposed to 10 ng/ml TNF-α for 30 minutes. 
Cells were washed using PBS and fixed in 4% paraformaldehyde (4% PFA, 15 min, RT). 
Permeabilisation and blocking was carried out as previously described [24]. NF-κB-p65 was detected 
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by immunostaining with p65 antibody (1:100, sc-8008, Santa Cruz Biotechnology), followed by 
incubation with Alexa fluor 488 goat anti-mouse IgG secondary antibody (Molecular probes 1:200) 
and mounting in medium containing 2.5μg/ml DAPI. Imaging was carried out using Zeiss Axioimager 
Epifluorescence microscope and p65 nuclear pixel intensity was measured using ImageJ software. 
 
NF-κB luciferase gene reporter assays U251 cells (Cell line Service, Eppelheim, Germany) were 
cultivated in Dulbecco’s Modified Eagle Medium (DMEM) high glucose (Sigma-Aldrich) containing 1% 
L-glutamine (200 mM, Sigma-Aldrich) and 10% FBS (Sigma-Aldrich) at 37◦C. Cells were transduced 
with the lentiviral pGreenFireTM-NF-κB-GFP-Luciferase Reporter construct (System Biosciences) and 
functionality was confirmed after puromycin selection (5 µg/ml, Apollo scientific) and clonal growth 
(data not shown). After cells were treated with 2% CM for 24 h, medium was removed and cells 
were treated with 10 ng/ml TNF-α.  Lysing of the cells was performed after 24 h using cell culture 
lysis buffer (Promega), and activity of luciferase was measured after applying firefly luciferase 
reporter assay system (Promega) according to manufacturer’s guidelines using Lucy 1 luminometric 
plate reader (Anthos).  
 
In Vivo Cardiotoxin induced Mouse TA Injury and AFSC CM/EV Treatment C57BL/6 mice (12 week 
old) were tail vein injected with 100μL either hAFSC CM, hAFSC EV or ultra-centrifuged PBS. 30 
Minutes later mice were injected with a total of 30μL 50μM Naja pallida cardiotoxin (CTX) (Latoxan, 
Valence France) into the tibialis anterior (TA). After 5 days mice were sacrificed and TA muscles were 
collected and immediately frozen.  
 
Histology Frozen Tibialis Anterior (TA) muscles were embedded in Tissue-TEK® OCT compound (PST). 
12μM cryo-sections were processed for immunohistochemistry [24]. With the following antibodies 
were used: monoclonal anti-mouse NF-κB-p65 (Santa Cruz 1:200); monoclonal anti-mouse Pax-7 
(Developmental studies hybridoma bank-DSHB 1:1); monoclonal anti-mouse Myosin heavy chain 3 
(Santa Cruz biotechnology 1:200); Rat anti-mouse CD31 (Bio-Rad 1:150); Rat anti-mouse F4-80 (Bio-
Rad 1:200); polyclonal Rabbit anti-MyoD (Santa Cruz biotechnology 1:200). All primary antibodies 
were pre-blocked in wash buffer for 30 min prior to use. The following secondary antibodies were 
used: Alexa fluor 488 goat anti-mouse IgG (Molecular probes 1:200), Alexa fluor 594 goat anti-mouse 
IgG (Molecular probes 1:200), rabbit anti-Rat HRP (DAKO 1:200).  
 
Uptake of PKH26-stained EVs by IMR-90 cells AF-EV staining was carried out using the PKH26 Red 
Fluorescent Cell Linker Kit (Sigma).  IMR-90 cells cultured until 70% confluency and treated for 3 
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hours with stained AF-EVs for 3 hours. Cells were washed twice with PBS and EV uptake visualised 
using a Zeiss Axioimager Epifluorescence microscope. 
 
Sample preparation for Mass Spectrometry (MS) AF-EV and non-EV fraction isolated from AFSCs 
secretome were obtained as described above. Proteins were suspended in SDS-PAGE loading buffer 
1x (NuPAGE, Invitrogen, Darmstadt, Germany), denaturated and reduced with 1 mM DTT for 10 min 
at 95°C then, alkylated using 5.5 mM iodoacetamide for 30 min at 25°C in the dark. Proteins were 
resolved by SDS-PAGE using 4-12% Bis-Tris mini gradient gels (NuPAGE, Life Technologies). Each lane 
was cut into 10 equal slices, proteins therein were in-gel digested with trypsin (Promega). Peptides 
were extracted, purified by STAGE tips, dried to less than 5µl and re-suspended in 15 µl of 0.5% 
acetic acid for the MS analysis.  
 
Mass Spectrometry Analysis LTQ Orbitrap XL mass spectrometers (Thermo Fisher Scientific) coupled 
to an Agilent 1200 nanoflow-HPLC (Agilent Technologies GmbH) were used to measure peptides 
derived from trypsin digestion. Samples, applied directly onto self-packed HPLC-column tips of 
around 20 cm, were subjected to a gradient formed by solution A (0.5% acetic acid in LC-MS  grade 
water) and by increasing organic proportion of solution B (0.5% acetic acid in 80% LC–MS grade ACN 
in water) within 120 min [25]. MaxQuant software version 1.4.1.2 was used to identify proteins 
based on peptides and to perform label-free quantification [26]. Both mass spectrometry and 
MaxQuant parameters were set as previously described [27]. The analysis of Molecular Function GO 
terms was performed trough Perseus software version 1.5.8.5 using Fisher’s exact test with a p-value 
threshold of 0.02 [28]. 
 
miRNA Array and analysis GeneChip® miRNA 4.0 Arrays were used to analyze the miRNA content of 
AF-EVs using FlashTag™ Biotin HSR RNA Labeling Kits according to the manufacturer´s instructions. 
Probe cell intensity data (CEL) from Affymetrix GeneChip miRNA 4.0 Arrays were analyzed in the 
Affymetrix Expression Console™ software. Normalization was performed using the Robust Multichip 
Analysis (RMA) + DABG algorithm [29]. Only miRNAs calculated as present in all 3 samples were 
declared as generally expressed after 24 hours. Focus was given to the miRNAs present with the 
highest signal intensities (top 50). For these top 50 miRNAs validated target mRNAs were 
amalgamated using miRWalk2.0 software [30]. In the next step, GO Slim classification for biological 
process was performed using WebGestalt software to provide a high-level functional classification 
for validated target mRNAs [31]. Morpheus software was used to design the Heat-map showing 
intensity variability between biological replica (n=3) for the top 50. 
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Transmission Electron Microscopy For TEM extracellular vesicle pellets were re-suspended in 40 µl 
of 0.1M PBS. Drops of these suspensions were placed on parafilm. Carbon-coated copper meshed 
grids (Plano, Germany) were placed on the drops for 5 minutes for probe adsorption. After five 
minutes of fixation on drops of 1% glutaraldehyde (Roth, Germany) grids were washed 4 times for 30 
seconds and negative contrasted using 1% uranyl acetate. Grids were air dried and analysed using a 
Zeiss 906 transmission microscope (Zeiss, Germany). 
 
Statistics All experiments were performed three times unless otherwise stated. Statistical analysis 
was performed using GraphPad Prism software. Data analysed between multiple groups was tested 
using one-way ANOVA followed by Tukey’s post-hoc testing. For comparison between two groups, 
independent sample t-tests were completed. Significance values were always set at the 95% 
confidence interval. All p values were indicated as p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). All 
data are displayed as mean ± SEM. 
 
Results 
AFSCs retained multipotency following the collection of AF-CM rich in protein and nucleic acid 
(Figure 1) 
AF-CM contained a high level of protein (834.25μg/ml ± 72.73) and a low level of nucleic acid 
(21.93μg/ml ± 2). Human AFSCs retained expression (Figure 1A-C) of mesenchymal stem cell markers 
CD44 (97.5%), C73 (92.7%), CD90 (42.7%) whilst being negative (Figure 1D-E) for CD45 (0.095%) and 
CD34 (5.92%). Following the collection of AF-CM under non physiological conditions, human AFSCs 
not only survived but were still able to expand in normal culture conditions. Additionally, human 
AFSCs cultured under differentiating conditions after CM collections were capable of undergoing 
adipogenesis, osteogenesis and chondrogenesis (Figure 1F-H’) confirming their multipotent 
differentiation capabilities. 
 
AF-CM is able to suppress NF-κB signalling (Figure 2A-E) 
The ability of AF-CM to modulate the inflammatory response was tested using U251 cells stimulated 
with TNF-α which resulted in an increase of nuclear NF-κB p65 (Figure 2D). Treatment with AF-CM 
for 24 hours before and during TNF-α stimulation led to a reduction in nuclear p65 by 42.5% from 
2.28±0.02 to 1.31±0.11 (Figure 2D), at levels comparable to  unstressed U251 control cells. Activity 
of NF-κB activity was quantitatively demonstrated using a NF-κB – Luciferase/GFP lentiviral infected 
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U251 cells (Figure 2E). TNF-α elevated the levels of NF-κB dependent luciferase by 46.3%, which was 
reduced by 15.4% to 40±1.63 with AF-CM. AF-CM treatment alone showed no change in NF-κB 
dependent luciferase activity compared to non-TNF-α stimulated control U251 cells. Therefore AF-
CM attenuates NF-κB activity, a transcription factor widely regarded to regulate pro-inflammatory 
signalling [32]. 
 
AF-CM modulates exogenous stem cell properties and protect against cellular stress (Figure 2F-G) 
The efficacy of AF-CM as a regulator of cellular behaviour was assessed by examining three 
properties: (i) the ability to reduce levels of cellular senescence, (ii) promote proliferation and (iii) 
migration. Firstly, we demonstrated a reduction in H2O2-induced senescence associated β-gal 
staining (Figure 2F) following AF-CM treatment stress exposure, from 88.75%±4.39 to 73.25%±1.89. 
Additionally, AF-CM increased the proliferation capability of Adipose Derived Mesenchymal Stem 
Cells (ADMSCs) at a range of concentrations (Figure 2G). The 30% increase in cell number attributed 
to the lowest concentration of AF-CM was similar to changes seen with higher CM concentrations, 
but 2.5% AF-CM induced the optimal increase in ADMSC migration in a wound closure assay (Figure 
2H). Therefore AF-CM demonstrates an ability to protect against senescence induced through stress 
as well as to promote the proliferation and migration of allogeneic stem cells.  
 
AF-CM enhances regeneration in an in-vivo acute muscle injury model (Figure 3) 
In order to directly assess its regenerative capabilities, AF-CM was intravenously injected into mice 
prior to injecting naja mossambica mossambica CTX intra-muscularly into the Tibilalis Anterior (TA).  
Expression of eMHC was used to identify newly regenerating muscle fibres (Figure 3A). Analysis of 
regenerating fibre cross sectional area (CSA) showed a dramatic 73.6% increase in fibre size (from 
381.12±4.43μm
2 
to 661.67±6.31 μm
2
) in the AF-CM treated mice (Figure 3B-C) particularly in those 
fibres sized 600μm. Since CTX does not directly affect the resident satellite cell population, 
endogenous stem cells become activated following fibre damage, subsequently differentiated into 
myoblasts and then fused to replace lost muscle fibres. Although the levels of quiescent 
Pax7
+
/MyoD
-
 and activated Pax7
+
/MyoD
+
 satellite cells did not significantly differ between CTX and 
CTX AF-CM treated mice, the level of muscle lineage committed Pax7
-
/MyoD
+
 progenitor cells was 
increased 76.4% in AF-CM treated mice (28.45±4.66 cells to 50.20±5.62 cells) compared to CTX 
treated controls (Figure 3D-E). Additionally, AF-CM treated mice had increased numbers of CD31 
positive capillaries per area of regenerating muscle (Figure 3G). More importantly the number of 
CD31
+
 positive vessels per fibre was increased 75% (from 0.96±0.10 to 1.68±0.25) when compared to 
the CTX treated controls (Figure 3H). Further examination uncovered a larger infiltration of cells 
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expressing the pan macrophage marker, F4-80
+
, within TA muscles of AF-CM treated mice compared 
to control CTX damaged mouse TAs (Figure 3I-J).   
 
AF-CM extracellular vesicle size is characteristic of exosomes and they are rich in miRNA (Figure 4) 
Step-wise ultracentrifugation was used to isolate the extracellular vesicles (AF-EV) from the AF-CM. 
The RNA profile showed that the AF-EV fraction was almost exclusively made up of small species 
(~21-25 nucleotides in size (Figure 4A)). Small RNAs such as miRNA are known to be vulnerable to 
enzymatic breakdown and have been proposed as being contained within extracellular vesicles 
released by cells for inter-cell communication [33,34]. Size analysis of vesicles was originally carried 
out to determine the type of vesicle being secreted by the AFSCs AF-CM (Figure 4B-C). Average 
vesicle diameter was 72.5±4.66 nm suggesting that the majority were exosomes. Levels of protein 
within the AF-EV were found to be very high (595 μg/ml). Vesicular proteins in the AF-EV were 
compared to those found in the whole AF-CM using silver staining (Figure 4D). Silver staining of 
proteins in the AF-EV revealed a higher concentration of proteins within the 40-50kDa range 
compared to the wide spectrum of proteins found in the AF-CM (Figure 4D). Fluorescent red PKH26 
stained AF-EVs were taken up by IMR-90 target cells and staining was found situated within the cells 
as opposed to the cell membrane (Figure 4E). 
 
AF-CM extracellular vesicles protect against cellular stress and suppress NF-κB activation (Figure 5) 
In vitro assays testing cellular protection from senescence and ability to reduce NF-κB activity were 
carried out to compare the AF-EV fraction to the whole AF-CM. The p65 nuclear translocation assay 
(Figure 5A-E) showed the AF-EV provided a 34.3% greater suppressive effect on the translocation 
compared to AF-CM (1.47±16.15 and 2.39±0.12 respectively). Quantitative evaluation of AF-EV NF-
κB activity via the luciferase based assay showed no change in luciferase expression compared to the 
AF-CM, (Figure 5F). The AF-EV fraction induced a decrease in the levels of H2O2-induced senescence 
by 78% (from 35.50±1.99 to 7.58±0.94, Figure 5G). However, there were no differences in 
senescence between the whole and AF-EV fractions. 
 
AF-EV retain the ability to enhance regeneration within an acute muscle injury model in-vivo 
(Figure 6) 
Regeneration of CTX damaged TA muscle was used to determine whether the AF-EV fraction 
promoted muscle regeneration. CSA of newly regenerating TA fibres was increased by AF-EV 
treatment compared to the CTX damage control (926.66μm
2
±24.23 and 484.51μm
2
±68.27 
respectively), resulting in a 91.2% increase in size of newly formed fibres (Figure 6A-B).  Levels of 
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CD31
+
 capillaries/fibre (Figure 6C-D) were also increased 29.7% (from 1.01±0.08 to 1.31±0.07 
capillaries/fibre) by the AF-EV treatment compared to the vehicle treatment. AF-EV treatment 
likewise amplified capillary density towards that similarly seen in an undamaged control mirroring 
what was observed AF-CM. On the other hand, levels of F4-80
+
 cells were not altered by the AF-EV 
treatment (Figure 6E-F). AF-EV treatment did not alter the levels of quiescent (Figure 6G), activated 
satellite cells (Figure 6H) and committed progenitor cells (Figure 6I) compared to that of the CTX 
damage control. In vivo analysis of AF-EV regenerative capabilities showed that treated mice 
presented with increased vascularisation and regenerating fibres with a larger CSA following CTX 
damage compared to vehicle treated controls. 
 
AF-EV harbour unique proteins and regeneration promoting miRNA (Figure 7-8) 
Mass spectrometry was used to identify proteins in both the AF-EV and non-EV fraction from the 
human AFSCs secretome (Figure 7B). A total of 856 protein groups were identified. A variety of 
proteins were found present in both the soluble fraction and EV fraction of the AF-CM (Figure 7A). 
However, a very distinctive quantitative protein profile was found in the EV fraction compared to the 
soluble fraction (Figure 7B). 416 protein species were shared between the two fractions. However 
250 protein species were unique to the soluble fraction whereas 190 species were exclusive to the 
AF-EV fraction (Figure 7a). Proteins enriched in the different AF-CM fractions were shown to be 
important in shared cellular processes (Table 1), cellular processes individual to that of the soluble 
fraction (Table 2) and processes only found to be controlled by proteins within the AF-EV fraction 
(Table 3). Of interest were the Heat-Shock family of proteins present in the AF-CM. A large number 
of Heat-Shock proteins were secreted, some of which were found only within the AF-EV fraction 
including HSPA (70kDa)-4L, whereas others were found only in the soluble fraction including the 
mitochondrial 60 kDa heat shock protein (HSPD-1). Finally many were found in both fractions e.g. 
HSPA-6 protein. Transmembrane transporters and receptors were enriched within the AF-EV 
including ABCE1, ABCF1, ABR, AP2A1, CYFIP1, CYFIP2, DNM1, DNM2, DNM3, HDAC2, HDAC1, HK1, 
MAPK1, NCKAP1, PPP1CB, ROCK2, RTN4, STRAP, USP9X, USP9Y and XPO1 (7B). A2B1 
ribonucleoprotein was also found in the AF-EV fraction, whilst no RISC complex associated proteins 
were found in either fraction.  
 
Detailed analysis of the AF-EV miRNA led to the identification of 586 miRNA species and 21399 
pathway targets (Figure 8B). The majority of miRNA were found to target mRNA controlling 
processes such as metabolic activity (Figure 8B) but also more specifically responses to stress (Figure 
8C). Within the top 50 miRNAs in the AF-EV, many were postulated to promote angiogenesis, 
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proliferation, migration, differentiation and autophagy such as miR382, miR24-3p and miR3960 [35-
37].  Other species of miRNA found potentially inhibit apoptosis, including miR3196, miR762, 
miR125b-5p and miR1273-3p [38-41]. Whilst others present such as miRNA let-7b-5p are known to 
also possess anti-inflammatory effects [42,43]. 
 
Discussion 
Our extensive characterisation of AF-CM and its AF-EV fraction created under non-physiological 
conditions from human AFSCs provides crucial information about their protein and RNA cargo. We 
demonstrated that human AFSC derived AF-CM and AF-EV were able to modulate allogeneic stem 
cell activity and inflammatory signalling. Our results showed that alterations in inflammatory 
signalling following treatment with AF-CM were mediated at least in part through NF-κB pathway 
repression.  Furthermore, our data suggests that many paracrine factors that support regeneration 
were in the AF-EV.  Interestingly, the RNA fraction of the secretome was made entirely of miRNA and 
lacked mRNA molecules. 
Much promise surrounds the clinical potential for MSCs in regenerative therapies. Foetal derived 
MSCs, such as AFSCs may have greater differentiation potential compared to their adult counterpart, 
such as adipose derived MSCs [22]. AFSCs are multipotent and promote regeneration of an array of 
tissues [4,9,22]. However, the ability of AFSCs and other stem cells to regenerate tissue is often 
through the paracrine acting secretome which include proteins and RNA molecules [4,8]. Paracrine 
factors are often found in membrane bound vesicles such as exosomes and microvesicles that aid 
transit for cell communication and protect the cargo from degradation [34].  Low levels of basal EV 
secretion are often increased after stress [14].  The ability to increase EV shedding following stress 
was proposed as a means to produce a more potent secretome [44]. Additionally, cell-free based 
therapies reduce the risk of immunological reactivity often associated with the use of whole cells. 
The potential for tumorigenesis using whole cells is also avoided and it is believed that cell-free 
therapies are a safer option for clinical use.  
Previous studies have either used whole stem cells or basal medium and/or serum derived CM 
collected under physiological conditions [4,10]. Collection of AF-CM in PBS, at room temperature as 
used in this study was postulated to induce cellular stress which would enhance the secretion of 
regenerative molecules [44]. It concords with a recent study which demonstrated that hypoxia 
promoted EV secretion from human AFSCs [45]. However in our study, we used even more severe 
conditions and demonstrated that not only did the human AFSCs survive 24 hours in non-optimal 
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nutrients, temperature and oxygen conditions but they still expressed multipotency markers CD90, 
CD73 and CD44 as well as retaining the adipogenic, osteogenic and chondrogenic potential. These 
results show that human AFSCs are extremely resilient which would be beneficial for not only 
surviving in a hostile cellular environment, which might exist in the uterus during gestation, but also 
in damaged tissue. 
A wealth of evidence shows that paracrine factors released by stem cells are packaged into small 
membrane bound EVs [10,34,46-48]. We isolated vesicles from our AF-CM which exhibited an 
average diameter of 72.5nM which is consistent with them being exosomes rather than 
microvesicles [34,49]. Protein analysis also provided evidence for the presence of exosomes due to 
the existence of known structure specific markers such as CD63, HSP70, HSP90, ACTB, GAPDH and 
14-3-3 protein zeta/delta (YWHAZ) [50,51]. AF-EV cargo profiling identified a number of 
polypeptides unique to this fraction. Presence of specific proteins within the AF-EV fraction and 
soluble fraction implies that both may have therapeutic value and contrasts suggestions promoting 
the use of AF-EV fractions alone [45].  Our data shows that although the AF-EV may provide the AF-
CMs principle effects, the use of the AF-EV alone could lead to the loss of potentially important 
protein species for regeneration.  
The library of excreted paracrine factors identified using mass spectrometry suggests that they alter 
the cellular signalling activity in target cells. Identification of Heat-shock proteins was of particular 
interest. For example the presence of Heat-shock protein 70 in the AF-CM which has been previously 
shown to initiate a preparatory like signalling mechanism in order to brace cells for incoming stress 
[52-54].  Furthermore, the ‘alarmin’ protein HMGB1 was present in the CM which may further 
potentiate the protective mechanisms [55]. A reduction in the level of H2O2-induced senescence 
following AF-CM treatment also showed a protective effect. The suggestion that there is a safe 
guarding against cellular stress following tissue necrosis could in part be explained by the presence 
of these alarmins within the AF-CM. In-vitro experiments showed that AF-CM increased proliferation 
and migration of ADMSCs, thus showing an ability to modulate allogeneic stem cell activity in favour 
of regeneration. AF-CM caused no aggravation of a pro-inflammatory response in itself. 
Interestingly, a capacity to reduce NF-κB-p65 nuclear translocation and TNF-α driven NF-κB activity, 
demonstrated the ability of AF-CM to reduce inflammation, a key characteristic required for 
regeneration [56].  
Our work also sheds light into the possible role of AFSCs in their natural environment, the amniotic 
fluid. It has been shown that there is an increase in p65 signalling towards the end of a pregnancy 
which is believed to help trigger labour. It is conceivable that AFSCs play a role in dampening p65 
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signalling and therefore prevent pre-term labour but also constrain a pro-inflammatory environment 
known to be damaging for the foetus [57-59]. We suggest that this is a regulated process such that 
periods of stress promote the secretion of anti-inflammatory molecules by AFCs into the amniotic 
fluid.  
Treating IMR-90 cells with PKH26 stained AF-EVs not only showed that AF-EVs were capable of being 
taken up by target cells but it also provided further evidence that uptake was via an active process. 
The lack of stained membrane lipid around the periphery of the cell and instead presence within the 
cell suggests that the AF-EV membranes did not fuse with the target cell membrane. Instead its 
uptake has been proposed to be facilitated by active mechanisms such as endocytosis, preparing 
cargo endocytic compartment sorting [60,61]. Membrane bound receptors and transporters are 
thought to aid the facilitation of EV fusion and uptake into target cells [34]. It has been previously 
hypothesised that EV adsorption is cell specific enabling  cellular responses such as angiogenesis 
[34,48]. Endothelial progenitor derived EVs targeting to endothelial cells is believed to be facilitated 
by surface alpha4 and beta1 integrins [48].  In contrast, our data shows a regenerative response for 
the AF-CM and AF-EV in a number of cell types.  In keeping with this, mass spectrometry profiling 
failed to find any specific cell surface targeting protein. These data therefore provide evidence that 
the AF-CM protective effects are not specific to one cell type but afford cellular protection to a 
spectrum of cell types. Again this is hypothesised to be of benefit during pregnancy to protect the 
foetus. This suggests that AF-CM may be therapeutically amenable for use in a number of 
pathological situations and tissues. 
The A2B1 ribonucleoprotein is known to transport miRNA into EVs. The presence of this protein in 
the AF-EV fraction supports the idea that loading of the miRNA in this compartment is a regulated 
process [62]. miRNA must be protected for long range transport and signalling due to their instability 
and susceptibility to enzymatic degradation. Protection can be facilitated via interaction with the 
RISC protein complex. However, mass spectrometry failed to detect RISC complex proteins. We 
suggest the role of providing miRNA stability is fulfilled by EVs. Packing of miRNA into EVs not only 
protects them from degradation but may be essential for their biological action. Indeed recent 
research has demonstrated that naked circulating miRNA has no biological activity. This property is 
imbued following their encasement in EV [13].  One very important finding of this study was that all 
the RNA in the CM was miRNA with no evidence of mRNA [33,48,63,64]. This signifies that AF-CM 
modifies endogenous programmes of the existing target cells rather than imposing ones that are 
completely foreign.  
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Enhanced regenerative properties of the EV fraction demonstrated here could be attributed to the 
presence of miR125b-5p, miR3196 and miR762, which target pro-apoptotic and senescence related 
mRNA [40]. Suppression of keap1 mRNA by miRNA125b-5p has been shown to inhibit both FAS 
induced apoptosis and APAP induced necrosis leading to the inhibition of acute liver failure [40]. In 
addition, targeting of the RNF4 gene by miR762 inhibits apoptosis by inducing DNA repair 
mechanisms [39].  The modulation of H2AX expression by miR3196 and downregulation of 
PUMA/p53/p21 signalling was shown to inhibit apoptosis but also suggests a subsequent 
suppression of downstream senescence [38]. Importantly some of the identified miRNAs, notably 
Let-7b,  have been previously shown to be anti-inflammatory [42]. A recent study by Balbi et al 
profiled miRNA in a AF-CM with regenerative properties [45].  However none of their candidates 
feature on the list of top 50 miRNA found in our samples. We suggest that the types of miRNA 
produced by human AFSCs depend on culture conditions and many miRNA regulate mRNA that 
control regeneration. 
Suppression of NF-κB signalling by the AF-EV fraction was shown to be equal to, or stronger than 
that of the whole AF-CM. This implies that the components subduing NF-κB activity reside mainly in 
the EV fraction. Our data provides direct evidence of AF-CM and AF-EV having anti-inflammatory 
effects through suppression of NF-κB signalling. Studies into the ability of AFSC CM to alter the 
polarisation of M1 to M2 macrophages will provide further evidence of its anti-inflammatory ability 
as was shown recently with adipose derived MSC CM [65]. Cellular protection may also derive from 
the vesicular portion of the CM as evidenced by a reduction in cellular senescence with AF-EV being 
equally potent as AF-CM. The regulation of NF-κB signalling homesis is important in both the 
determination of the inflammatory response but also many other directly and indirectly related 
pathways such as cellular growth, proliferation and the stress response [66,67]. These results 
suggest that the AF-CM including its EV fraction may drive signalling towards a normal equilibrium 
like-state. 
Our results show that both the CM and EV from AF cells promote muscle regeneration. However we 
believe that the subtle differences in the results from these two experiments offer not only 
mechanistic insights into how this is occurring but also the relative importance of differing factors in 
the process. Whole CM experiment showed an increase in the number of committed muscle cells 
(Pax7
+
/MyoD
+
), an increase in capillary density and increased number of macrophages. Capillary 
density but not macrophage infiltration was changed in the EV experiment compared to controls. 
Furthermore in the EV experiment, the number of activated precursor muscle cells was increased. 
These results suggest that the supra-basal infiltration of macrophages is not a key determinant in 
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this study to the enhanced fibre regeneration effect of AF-CM or AF-EV. AF-CM and AF-EV 
treatments both increased the capillary density. A highly vascularised tissue is documented to 
support regeneration [68].   Indeed recent work shows that an enhancement in vascularisation can 
overcome even a deficit in muscle stem cell numbers to promote muscle regeneration [68].  We 
suggest that the impressive enhancement in muscle regeneration seen after AF-EV treatment is due 
to a combined effect of not only increased capillary density but also an increase in the number of 
Pax7
+
/MyoD
+
 cells. A number of studies have shown that these cells undergo more rapid division 
than committed Pax7
-
/MyoD
+
 cells [69]. We suggest that constant supply of precursors in a highly 
vascularised environment, promoted by AF-EV, results in superior regeneration compared to AF-CM 
treatment. 
 
Notably, our in vitro results were in general accordance with the data obtained in the in-vivo model 
of muscle regeneration. Our data showed that both AF-CM and AF-EVs accelerated muscle 
regeneration after CTX damage. The most obvious sign of regeneration was the enhanced CSA of 
newly regenerating fibres 5 days after damage. Both the AF-CM and AF-EV doubled the size of 
regenerating fibres. Our data directly showed significant evidence of increased levels of capillary 
density following AF-CM ( 3F-H) and AF-EV ( 8C-D) [45]. The level of angiogenesis during 
regeneration has been suggested as being more important than the number of satellite cells present 
[68]. Let7b has been linked to function as a pro-angiogenic miRNA as well as miR382, which was also 
found to be present and previously demonstrated to promote angiogenesis via PTEN repression 
[35,43]. The increase in F4-80
+
 cells following AF-CM treatment could be due to the time frame in 
which muscles were collected following damage. Hypothetically the increase in macrophage 
numbers is due to a surge in anti-inflammatory M2 macrophages. However, unlike the AF-EV, the 
AF-CM significantly elevated the number of Pax7
-
/MyoD
+
 myogenic committed progenitor cells. A 
greater level of committed cells in the CM treated mice along with the increased exogenous stem 
cell migration and proliferation in-vitro evokes the possibility that AF-CM enhances satellite cell 
proliferation and migration. This would lead to increased levels of myogenic committed cells seen 5 
days later upon dissection. More myogenic progenitor cells would also account for an increased fibre 
size due to elevated myoblast fusion events. To summarise, the whole AF-CM had an ability to 
increase regenerating fibre size, increased the number of capillaries/fibre and increase the level 
committed muscle progenitors available. On the other hand, the AF-EV was shown only to retain the 
ability to increase the regenerating fibre size and the number of capillaries/fibre.  Although AF-EV 
fraction is able to promote regeneration, these results imply that the use of whole AF-CM may be 
more beneficial therapeutically than AF-EV fraction alone because it mediated wider regenerative 
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effects. The array of factors both in the soluble and AF-EV fraction could provide more means of 
regeneration compared to that of the AF-EV alone. On the other hand, in the case of miRNA, there is 
strong evidence suggesting that it can only significantly alter the signalling of other cells when 
packaged, secreted and intercepted within EVs [13]. 
In summary we show that AF-CM produced from human AFSCs under conditions compliant with 
clinical translation contained a spectrum of proteins and miRNA as the predominant molecular 
species.  The secretome was shown to regulate key stem cell activities as well as promoting skeletal 
muscle regeneration. AF-CM contained exosomes which carried a unique cargo which in itself was 
able to promote muscle regeneration. Proteomic and molecular profiling of the cargo identified 
molecules capable of modulating inflammation and angiogenesis which could mechanistically 
underpin tissue regeneration. Future investigations will focus on specific cargo molecules for their 
ability to promote the repair of tissue. 
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Category value 
Selection 
size 
Category 
size 
Enrichment 
factor P value 
Benj. 
Hoch. 
FDR 
nucleic acid metabolic process 112 126 2,5057 2,66E-33 8,10E-27 
RNA metabolic process 112 105 2,6531 2,88E-30 4,38E-24 
metabolic process 192 297 1,3423 9,33E-28 9,46E-22 
proteolysis 32 42 8,3571 8,10E-27 4,92E-21 
Aminoacyl-tRNA biosynthesis 13 13 32 6,73E-25 8,87E-20 
proteolysis 21 42 9,9048 4,58E-24 9,29E-19 
small molecule metabolic process 192 112 1,8571 5,27E-24 1,00E-18 
tRNA metabolic process 13 14 29,714 9,43E-24 1,51E-18 
nucleobase-containing compound metabolic process 112 159 2,0323 1,03E-23 1,56E-18 
ribonucleoprotein complex 78 58 3,8621 3,95E-23 1,74E-17 
regulation of gene expression 112 107 2,3605 1,74E-21 2,52E-16 
cytoskeleton 49 81 3,9829 1,24E-21 2,73E-16 
nucleic acid metabolic process 48 126 3,0265 2,17E-21 3,00E-16 
ncRNA metabolic process 13 18 23,111 5,77E-21 7,02E-16 
primary metabolic process 192 279 1,3357 6,13E-21 7,17E-16 
regulation of RNA metabolic process 112 78 2,619 1,05E-19 1,18E-14 
RNA processing 78 42 4,1905 1,85E-19 2,01E-14 
regulation of catalytic activity 29 62 5,7842 2,53E-19 2,66E-14 
nitrogen compound metabolic process 112 183 1,8064 3,14E-19 3,19E-14 
cellular nitrogen compound metabolic process 112 180 1,8159 4,90E-19 4,81E-14 
regulation of RNA metabolic process 48 78 3,8889 6,94E-19 6,59E-14 
mRNA metabolic process 78 46 3,942 1,33E-18 1,23E-13 
RNA processing 112 42 3,2721 1,44E-18 1,29E-13 
mRNA metabolic process 112 46 3,1491 2,33E-18 2,02E-13 
 
 
 
 
 
 
 
 
Table. 1 Soluble and Extracellular Vesicles GOMF terms enrichment 
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Table. 2 Soluble only GOMF terms enrichment 
Category value Selection Category 
Enrichment 
factor P value 
Benj. 
Hoch. 
FDR 
translational initiation 13 12 17,628 1,94E-16 3,05E-10 
regulation of translational initiation 13 10 19,231 1,31E-15 1,02E-09 
translational initiation 15 12 15,278 3,37E-15 1,76E-09 
regulation of gene expression 46 63 2,9331 4,56E-15 1,79E-09 
regulation of translational initiation 15 10 16,667 1,37E-14 3,07E-09 
regulation of macromolecule biosynthetic process 46 53 3,1788 1,21E-14 3,16E-09 
regulation of cellular macromolecule biosynthetic 
process 46 53 3,1788 1,21E-14 3,79E-09 
regulation of cellular biosynthetic process 46 55 3,0632 5,54E-14 9,66E-09 
regulation of biosynthetic process 46 55 3,0632 5,54E-14 1,09E-08 
nucleic acid metabolic process 23 47 4,6253 6,93E-14 1,09E-08 
translational initiation 26 12 9,6154 1,01E-13 1,33E-08 
regulation of translation 15 14 13,095 9,88E-14 1,41E-08 
regulation of transcription, DNA-dependent 23 38 5,1487 5,90E-13 7,12E-08 
translation 13 10 17,308 7,74E-13 8,67E-08 
regulation of translation 13 14 13,736 1,24E-12 1,30E-07 
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Table. 3 Extracellular Vesicles only GOMF terms enrichment 
Category value Selection Category 
Enrichment 
factor P value 
Benj. 
Hoch. 
FDR 
Ribosome 28 28 6,7857 3,87E-34 2,17E-29 
viral transcription 28 28 6,7857 3,87E-34 8,96E-29 
translational termination 28 28 6,7857 3,87E-34 1,20E-28 
protein complex disassembly 28 28 6,7857 3,87E-34 1,79E-28 
cellular protein complex disassembly 28 28 6,7857 3,87E-34 3,58E-28 
viral reproductive process 28 29 6,5517 1,12E-32 1,16E-27 
viral infectious cycle 28 29 6,5517 1,12E-32 1,30E-27 
translational elongation 28 29 6,5517 1,12E-32 1,49E-27 
macromolecular complex disassembly 28 29 6,5517 1,12E-32 1,73E-27 
cellular macromolecular complex disassembly 28 29 6,5517 1,12E-32 2,08E-27 
SRP-dependent cotranslational protein targeting to 
membrane 28 30 6,3333 1,68E-31 1,04E-26 
protein targeting to membrane 28 30 6,3333 1,68E-31 1,11E-26 
protein targeting to ER 28 30 6,3333 1,68E-31 1,20E-26 
nuclear-transcribed mRNA catabolic process 28 30 6,3333 1,68E-31 1,30E-26 
establishment of protein localization in endoplasmic 
reticulum 28 30 6,3333 1,68E-31 1,42E-26 
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Figure 1: AF-CM content and multipotency of post-CM generated AFSCs. Flow cytometry analysis for (A) 
CD44 (B) CD73, (C) CD90 (D) CD45, (E) CD34. (F-H) AFSCs cultured in growth media. AFSCs cultured in 
adipogenic (F’) osteogenic (G’) and chondrogenic (H’) media. (F, H) Scale bar equal to 50µm, (H) equals 
100µm.  
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Figure 2: In-vitro assessment of biological activity of whole AF-CM. (A-C) U251 cells stained for NF-κB-p65 
(green) (n=4). (D) Nuclear translocation of p65 analysed by intensity measurement. Green and white 
arrows representative of weak and strong nuclear localisation respectively. (E) NF-κB quantification. (F) 
Protection against H2O2-induced senescence compared to non-stressed U251 cells (NS). (G) Cell number 
relative to controls (0%). (H) Wound closure assay. (A-C) Images taken at 20x Magnification. Scale 
represents 50µm. Values are expressed as mean ± SEM (n=4). p < 0.05 (*), p < 0.01 (**) or p < 0.001 
(***)  
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Figure 3: AF-CM and muscle regeneration. (A) embryonic Myosin heavy chain expression in damaged 
muscle  (green). (B) Quantification of cross sectional area of newly regenerated fibres. (C) Frequency 
distribution graph of regenerated muscle fibres. (D) Immunofluorescent staining for Pax7 (green), MyoD 
(Cyan) and DAPI (Magenta). (E) Quantification of quiescent satellite Pax-7+/MyoD-, activated satellite cells 
Pax-7+/MyoD+ and muscle lineage committed progenitor cells Pax-7-/MyoD+. (F) CD31 staining for 
capillaries in regenerating muscle. (G) Quantification of capillary density (number per mm2) and (H) 
quantification per fibre. (I) F4-80 staining for macrophages (J) damaged areas assessed for the number of 
F4-80+ cells. Black arrows indicate F4-80+ cells. (A) Scale bars are equal to 100µm. (D, F, I) Scale bar 
represents 50µm. Values are expressed as means ± SEM (n=5). p < 0.05 (*), p < 0.01 (**) or p < 0.001 
(***)  
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Figure 4: Characterisation of AF-CM and AF-EV fraction. (A) Bioanalyser profile of RNA size (s) and 
frequency (FU) in AF-EV. (B) Size-frequency distribution plot of AF-EVs. (C) Electron micrograph images of 
AF-EV. (D) AF-CM and AF-EV fraction protein silver staining. (E) Uptake of PKH26+ AF-EV (red) by IMR-90 
cells (red arrows). (E) Scale bar representative of 20µm. p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***)  
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Figure 5: In-vitro assessment of biological activity of AF-EV. (A-D) U251 cells stained for NF-κB-p65 (green) 
immunofluorescence (n=4). (E) Nuclear translocation of p65 analysed by intensity measurement. (F) NF-κB 
quantification. (G) H2O2 Stressed IMR-90 cells treated with AF-CM or AF-EV CM compared to a non-stressed 
control (NS). Images were taken at a 20x Magnification. Green and white arrows representa ive of weak and 
strong nuclear localisation respectively. Scale bar represent 50µm. Values are expressed as means ± SEM 
(n=4). p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***)  
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Figure 6: AF-EV and muscle regeneration. (A) embryonic Myosin heavy chain expression in damaged 
muscle  (green). (B) Quantification of cross sectional area of newly regenerated fibres. (C) CD31 staining for 
capillaries in regenerating muscle. (D) Quantification of CD31+ capillaries per fibre. (E) F4-80 staining for 
macrophages. (F) Damaged areas assessed for the number of positive F4-80 cells/mm2. Comparison of the 
number of Pax-7+/MyoD- quiescent satellite cells (G), Pax-7+/MyoD+ activated satellite cells (H) and Pax-
7-/MyoD+ muscle lineage committed progenitor cells (I) per mm2 between treated groups. Values are 
expressed as means ± SEM (n=5). (A) Scale bar equal to 100µm. (C, E) Scale bar represent 50µm. p < 
0.05 (*), p < 0.01 (**) or p < 0.001 (***)  
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Figure 7: Mass spectrometry analysis and comparison between the AF-EV and AF CM soluble fraction. (A) 
Number of proteins shared and specific to the AF-EV or soluble fraction. (B) Heat map of GO-terms found in 
the AF-EV and resulting soluble fraction.  (C) Transmembrane transporters and receptors enriched in AF-EV 
fraction.  
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Figure 8: Profiling of AF-EV miRNA content (n=3). (A) Top 50 expressed miRNAs. (B) General cell processes 
targeted by all miRNA present. (C) Specific cellular processes and signalling pathways targeted by the 
miRNA present.  
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Supplementary Figure 1:  (A) Flow cytometry analysis of AFSCs post CM collection for original selection 
marker CD117.  (B) IMR-90 cells stained for senescence associated beta-galactosidase following H2O2 
induced stress. Scale bar equal to 20µm  
 
 
150x91mm (300 x 300 DPI)  
 
 
Page 38 of 38
Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801
Stem Cells and Development
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
